aTYR PHARMA (ATYR) Short-term Investments (2014 - 2026)

aTYR PHARMA (ATYR) has reported Short-term Investments for 13 consecutive years, with $41.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments fell 34.64% year-over-year to $41.3 million; the trailing twelve-month figure through Jun 2026 stood at $41.3 million (down 34.64% YoY), and the FY2025 full-year result was $67.9 million, up 11.26% from the prior year.
• Short-term Investments retreated to $41.3 million in Q2 2026 per ATYR's latest filing, from $56.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $96.3 million in Q2 2023 and bottomed at $41.3 million in Q2 2026.
• Historically, Short-term Investments has averaged $71.5 million across 5 years, with a median of $69.8 million in 2024.
• The widest YoY moves for Short-term Investments: up 137.43% in 2022, down 46.8% in 2022.
• Over 5 years, Short-term Investments stood at $56.2 million in 2022, then jumped by 34.64% to $75.6 million in 2023, then slipped by 19.24% to $61.1 million in 2024, then increased by 11.26% to $67.9 million in 2025, then tumbled by 39.28% to $41.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $41.3 million, $56.5 million, and $67.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.